These innovative agents represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://iwanvfxr231270.blogofchange.com/39779047/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide